Wednesday, July 8, 2026

Drug profile · INN

adefovir dipivoxil

adefovir dipivoxil (HEPSERA) is a dna polymerase/reverse transcriptase inhibitor. Route of administration: oral. Current US regulatory status: approved.

FDA: approved EMA: withdrawn Antiinfectives for systemic use (J05) J05AF08
US status approved
Patents linked 10
Pipeline programs 6
News articles 0
Drug details — adefovir dipivoxil
US status
approved
Class
Antiinfectives for systemic use (J05)
Route
ORAL
Patents
10
Programs
6
Data quality
0.84

Quick answer

adefovir dipivoxil (HEPSERA) is a dna polymerase/reverse transcriptase inhibitor. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN adefovir dipivoxil
Brand HEPSERA
Mechanism DNA polymerase/reverse transcriptase inhibitor
Target DNA polymerase/reverse transcriptase
Therapeutic class Antiinfectives for systemic use (J05)
Route ORAL
Formulation TABLET
ATC code J05AF08

Mechanism of action

DNA polymerase/reverse transcriptase inhibitor

Primary target: DNA polymerase/reverse transcriptase

Approval history

Authority Status Date
FDA approved
EMA withdrawn

Pipeline programs

  1. IP Phase 3 · Solid Biosciences · Small Cell Lung Cancer
  2. VOX Phase 2 · Gilead Sciences Ireland · Hepatitis C Virus Infection
  3. IP Phase 1 · Nurix Therapeutics · Healthy Volunteers
  4. Adefovir Approved · Chinese Academy of · Hepatitis B, Chronic
  5. adefovir dipivoxil Approved · GSK Glaxo Smith · Hepatitis B, Chronic
  6. adefovir dipivoxil Unknown · Hospital Authority · Hepatitis B

Related & competitor drugs

  1. atazanavir sulfate Antiinfectives for systemic use (J05)
  2. colistimethate sodium Antiinfectives for systemic use (J01)
  3. covid-19 mrna vaccine Antiinfectives for systemic use (J07)
  4. daptomycin Antiinfectives for systemic use (J01)
  5. darunavir Antiinfectives for systemic use (J05)
  6. dengue tetravalent vaccine (live, attenuated) Antiinfectives for systemic use (J07)

Related patents

  1. US 12377106

    Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading BTK

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 12234230

    Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 12049471

    Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof

    Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 11951133

    3-substituted piperidine compounds for Cbl-b inhibition, and use thereof

    Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 11866442

    Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 11820781

    Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway

    Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 11530229

    Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof

    Expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 11479556

    Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway

    Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 11464802

    3-substituted piperidine compounds for Cbl-b inhibition, and use thereof

    Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 11401267

    Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof

    Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is adefovir dipivoxil?

adefovir dipivoxil (HEPSERA) is a dna polymerase/reverse transcriptase inhibitor. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for adefovir dipivoxil?

HEPSERA is a marketed brand name for adefovir dipivoxil. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of adefovir dipivoxil?

adefovir dipivoxil has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.